国药控股(01099.HK)发布年度业绩，归母净利润71.55亿元 同比增加1.5% 末期股息每股0.69元

Group 1 - The company, China National Pharmaceutical Group (国药控股), reported revenue of RMB 575.168 billion for the fiscal year ending December 31, 2025, representing a year-on-year decrease of 1.6% [1] - The profit attributable to equity holders of the parent company was RMB 7.155 billion, reflecting a year-on-year increase of 1.5% [1] - Earnings per share were reported at RMB 2.29, with a proposed final dividend of RMB 0.69 per share [1]